Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-cell
therapy in multiple myeloma (MM). Despite promising objective response rates, most …

CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T-cell therapy has shown
significant efficacy for relapsed or refractory (R/R) B-cell malignancies. Yet, CD19 CAR T …

Background: Despite advances in the treatment of multiple myeloma (MM) almost all patients
relapse and high risk features continue to portend a short median survival. The adoptive …

Background γ-Secretase inhibitors (GSIs) increase B cell maturation antigen (BCMA) density
on malignant plasma cells and enhance antitumour activity of BCMA chimeric antigen …

BACKGROUND Little is known about pathogen-specific humoral immunity after chimeric
antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies. METHODS We …

Background: Although the median survival for patients with multiple myeloma has improved
dramatically, almost all patients will eventually relapse and become resistant to standard …

… Green… Damian J. Green: Consultant/Advisory Role: June Therapeutics. Trisha Wise-Draper:
Research Funding: Merck & Co., Inc. Juan G. …

The role of the immune microenvironment in maintaining disease remission in patients with
multiple myeloma (MM) is not well understood. In this study, we comprehensively profile the …

Therapy of cancer with radiolabeled monoclonal antibodies has produced impressive results
in preclinical experiments and in clinical trials conducted in radiosensitive malignancies, …